HC Wainwright & Co. Assumes OnKure Therapeutics at Buy, Announces Price Target of $40

Benzinga · 10/17 13:42
HC Wainwright & Co. analyst Robert Burns assumes OnKure Therapeutics (NASDAQ:OKUR) with a Buy rating and announces Price Target of $40.